Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;29(suppl):S5-S16.
doi: 10.3350/cmh.2022.0424. Epub 2022 Dec 28.

Non-alcoholic fatty liver disease: Definition and subtypes

Seul Ki Han  1   2   3 , Soon Koo Baik  1   2   3 , Moon Young Kim  1   2   3
Affiliations
Review

Non-alcoholic fatty liver disease: Definition and subtypes

Seul Ki Han et al. Clin Mol Hepatol. 2023 Feb.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide, with a global prevalence of approximately 30%. However, the prevalence of NAFLD has been variously reported depending on the comorbidities. The rising prevalence of obesity in both the adult and pediatric populations is projected to consequently continue increasing NAFLD prevalence. It is a major cause of chronic liver disease worldwide, including cirrhosis and hepatocellular carcinoma (HCC). NAFLD has a variety of clinical phenotypes and heterogeneity due to the complexity of pathogenesis and clinical conditions of its occurrence, resulting in various clinical prognoses. In this article, we briefly described the basic definition of NAFLD and classified the subtypes based on current knowledge in this field.

Keywords: Fibrosis; Non-alcoholic fatty liver disease; Steatohepatitis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

The authors have no conflicts to disclose.

Comment in

References

    1. The Lancet Gastroenterology Hepatology Redefining non-alcoholic fatty liver disease: what’s in a name? Lancet Gastroenterol Hepatol. 2020;5:419. - PubMed
    1. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357. - PubMed
    1. Sberna AL, Bouillet B, Rouland A, Brindisi MC, Nguyen A, Mouillot T, et al. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of nonalcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes. Diabet Med. 2018;35:368–375. - PubMed
    1. Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, et al. Korean Association for the Study of the Liver (KASL) KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2021;27:363–401. - PMC - PubMed
    1. Chang Y, Jung HS, Cho J, Zhang Y, Yun KE, Lazo M, et al. Metabolically healthy obesity and the development of nonalcoholic fatty liver disease. Am J Gastroenterol. 2016;111:1133–1140. - PubMed

MeSH terms